Abstract
C3 glomerulopathy represents a heterogeneous group of glomerulopathies characterized by hyperactivity of the alternative complement pathway. Although the pathophysiology is incompletely understood, an association between this disease and monoclonal gammopathies is increasingly recognized, especially in older individuals. There is still some uncertainty regarding the best treatment for patients with monoclonal gammopathy-associated C3 glomerulopathy. However, recent evidence suggests that myeloma-targeted therapies are associated with improved renal outcomes compared with conservative or conventional immunosuppressive therapies. This case report describes the clinical course and long-term follow-up of a patient with monoclonal gammopathy-associated C3 glomerulonephritis treated with myeloma-targeted therapy.